Engineering liposomal nanoparticles for targeted gene therapy

Purpose: Liposome-mediated gene delivery faces systemic barriers, endosomal escape, lysosomal degradation, and nuclear uptake limitations, while interactions between lipid nanoparticles and cells remain poorly understood. Rational design of targeted liposomes is needed to reduce off-target effects and enhance transfection, but no successful clinical targeted liposomal gene therapy system has yet been developed.

Hypothesis: As a review, there is no single experimental hypothesis. Central thesis: if liposomal nanoparticles are engineered with optimized physicochemical properties—lipid-to-DNA charge, size, ester bonds, chain length, helper lipid, linker chemistry, and targeting-ligand complexation—then they can overcome biological barriers, improve targeted nucleic acid delivery, and advance clinical gene therapy.

Aims: Review the latest breakthroughs in targeted liposome-based agents for genetic material delivery. - Focus on new ligand and cationic lipid design and recent in vivo advances. - Discuss barriers to efficient in vivo clinical systems: presystemic, systemic, and cellular barriers. - Examine rational physicochemical design of cationic liposomes, including helper lipids, cationic lipid architecture, linker design, and headgroup engineering. - Compare targeted strategies using peptides, antibodies, aptamers, and folate in vitro and in vivo.

Delivery system: Platform: Liposomal nanoparticles, cationic liposomes, lipoplexes. - Payloads: plasmid DNA, siRNA, CpG oligodeoxynucleotides, reporter genes, therapeutic genes. - Cationic lipids: DOTAP, DC-Chol, DOTMA, DLinDMA, DLin-KC2-DMA, DOC, EHCO, ECO, ECLn, DDCTMA, MSO9, Chol-DMAP, Chol-PR, multivalent cationic lipids (MLVs). - Helper/neutral lipids: DOPE, DOPC, cholesterol, DSPC, DSPE, monoolein, tetraether lipid analogues. - Linkers: ether, carbonyl, ester, amido, carbamoyl; acid-labile, enzyme-triggerable, and cleavable PEG linkers. - Targeting ligands: peptides (RGD, cyclic RGD, TAT, CPPs, AG73), antibodies (anti-HER2, OX26 anti-transferrin receptor, anti-TAG-72, anti-EphA10, anti-myosin), aptamers (anti-TfR c2.min, AS1411, IL-4Rα), and folic acid/folate. - Surface modification: PEGylation in every in vivo approach surveyed; dual-targeting and combination with chemotherapeutics also discussed.

Approach: Review/synthesis of in vitro and in vivo studies from the past 5 years. In vitro models include HeLa, MCF-7, HEK293, A375, B16-F10, SKOV-3, KB, HepG2, and others. In vivo models are mostly mouse tumor models, with systemic administration for tumor targeting; some brain glioma, melanoma, lung metastasis, and hepatic tumor models. Clinical translation has not yet been achieved. Not a systematic review.

Key methods: Transfection efficiency measured as gene expression normalized to cell number; fluorescence reporters; target gene knockdown/silencing; zeta potential and particle size; biodistribution and ex vivo imaging; tumor growth/viability; immune cytokine readouts; microfluidic synthesis for monodisperse liposomes; SELEX for aptamer selection.

Key results: No successful clinical targeted liposomal gene therapy product has emerged. - Microfluidic nanoscale liposomes encapsulating siRNA achieved 50% target gene silencing in hepatocytes at 10 µg/kg siRNA in mice. - Anti-TfR aptamer c2.min liposomes showed ~80–90% knockdown efficiency in HeLa cells. - AS1411 aptamer-liposomes achieved 34.13% BRAF gene silencing in A375 cells and accumulated in tumor xenografts. - IL-4Rα aptamer-liposome-CpG showed >2-fold higher FAM intensity than untargeted liposomes, inhibited myeloid-derived suppressor cells, and enhanced TNF-α, IL-2, and IL-12. - Folate-targeted liposomes gave 2-fold higher transfection than non-targeted in HeLa/HEK293 cells (~2.5×10⁸ RLU/mg protein); folic acid lipopolypexes gave 27-fold higher luciferase expression than non-targeted. - Anti-EphA10 pH-sensitive liposomes delivering MDR1-siRNA showed 4.42-fold higher delivery than without EphA10 and 1.67-fold higher than standard liposome. - OX26/CTX dual-targeted PEGylated liposomes delivering pC27 decreased tumor cell viability to 46% in brain glioma-bearing rats. - In vivo targeting was most effective with antibody- and aptamer-based ligands; PEGylation was used in every in vivo approach surveyed. - Ideal targeted liposomal vector: low toxicity, high stability, small size (<100 nm), neutral surface charge, extended serum half-life (>2–4 h), and moderate immunogenicity.

Interpretation: Traditional liposome therapeutics have achieved commercial success, but targeted liposomal gene delivery has not yet reached the clinic. Recent sophisticated ligand–cationic lipid complexes exploit expanding knowledge of bilayer amphiphiles, yet efficient gene delivery remains challenging. Targeting ligands can reduce systemic loss and non-specific binding, but adding a targeting moiety does not guarantee transfection. Clinical success is expected to rely on improved carrier–ligand design, antibody- and aptamer-based targeting, dual-targeting systems, and combination treatments uniting targeted gene delivery with therapeutic drugs.

Limitations: This is a review, not a primary study. No successful clinical system has been developed. Most studies remain in vitro, with fewer in vivo examples, and in vivo work largely uses reporter genes. Poor in vitro–in vivo correlations persist. The optimal helper lipid composition is still unresolved. Immunogenicity of antibodies, stability of aptamers, nonspecific folate interactions, RES clearance, serum degradation, endosomal escape, and manufacturing/scalability remain unresolved barriers. More in vivo data are needed before clinical conclusions can be drawn.